Zura Bio Limited (ZURA)
(Delayed Data from NSDQ)
$4.38 USD
+0.23 (5.54%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.40 +0.02 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Zura Bio Limited falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 100 | 0 | 1 | -99,999 | -99,999 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 1 | 0 | 0 | NA | NA |
Total Current Assets | 101 | 0 | 1 | NA | NA |
Net Property & Equipment | 0 | 0 | 0 | NA | NA |
Investments & Advances | 0 | 141 | 139 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 0 | 0 | 0 | NA | NA |
Total Assets | 101 | 142 | 141 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 0 | 0 | 0 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 20 | 1 | 0 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 0 | 0 | 0 | NA | NA |
Total Current Liabilities | 20 | 2 | 0 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 0 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 1 | 147 | 149 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 21 | 149 | 150 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 0 | 0 | 0 | NA | NA |
Capital Surplus | 163 | 0 | 0 | NA | NA |
Retained Earnings | -103 | -8 | -9 | NA | NA |
Other Equity | 20 | 0 | 0 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 80 | -8 | -9 | NA | NA |
Total Liabilities & Shareholder's Equity | 101 | 142 | 141 | NA | NA |
Total Common Equity | 80 | -8 | -9 | 0 | 0 |
Shares Outstanding | 43.00 | 3.40 | 17.20 | NA | NA |
Book Value Per Share | 1.85 | -2.24 | -0.53 | 0.00 | 0.00 |
Fiscal Year End for Zura Bio Limited falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 188 | 90 | 100 | 104 | 113 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 189 | 90 | 101 | 105 | 113 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 190 | 90 | 101 | 105 | 113 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 15 | 0 | 17 | 20 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 20 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 15 | 20 | 17 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16 | 1 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 31 | 28 | 21 | 19 | 22 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 278 | 172 | 163 | 158 | 156 |
Retained Earnings | -122 | -111 | -103 | -95 | -87 |
Other Equity | 2 | 2 | 20 | 22 | 22 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 158 | 63 | 80 | 86 | 91 |
Total Liabilities & Shareholder's Equity | 190 | 90 | 101 | 105 | 113 |
Total Common Equity | 158 | 63 | 80 | 86 | 91 |
Shares Outstanding | 63.70 | 43.50 | 43.00 | 43.00 | 43.00 |
Book Value Per Share | 2.48 | 1.44 | 1.85 | 1.99 | 2.12 |